Company:  VISTAGEN THERAPEUTICS, IN ... (VTGN)
Form Type:  8-K
Filing Date:  3/14/2019 
CIK:  0001411685 
Address:  343 ALLERTON AVENUE 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  650-577-3600 
Fiscal Year:  03/31 
Last Trade
Last Trade: 
$0.74  
Change: 
-0.0161 (-2.12%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$31.71M
Trade VTGN now with 

© 2019  
Description of Business
We are a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other diseases and disorders of the central nervous system (CNS) with high unmet need. Our lead CNS product candidate, AV-101, is an oral, non-opioid and non-sedating therapy that we believe offers the potential to be a new at-home treatment for multiple CNS indications with high unmet medical need. These indications include potential use as a new generation treatment alternative for Major Depressive Disorder (MDD), as a non-addictive, non-sedating option for management of chronic neuropathic pain (CNP), to reduce dyskinesia induced by levodopa therapy for Parkinson's disease (PD LID), and additional CNS indications where modulation of NMDA (N-methyl-D-aspartate) receptor and AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor pathways may achieve therapeutic benefit.
Register and access this filing in:     
  FORM 8-K
    SECTION 7 REGULATION FD
      Item 7.01 Regulation FD Disclosure.
    SECTION 8 OTHER EVENTS
      Item 8.01 Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    Signatures
    EXHIBIT INDEX
  EXHIBIT 99.1
  EXHIBIT 99.2